Article

Cancer Immunity, Vol. 10, p. 1 (7 January 2010) Submitted: 13 October 2009. Accepted: 25 November 2009.

Erratum in: Cancer Immunity, Vol. 10, p. 5 (24 February 2010)

Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy

Jianda Yuan1, David B. Page2, Geoffrey Y. Ku1, Yanyun Li1, Zhenyu Mu1, Charlotte Ariyan1, Humilidad F. Gallardo1, Ruth-Ann Roman2, Agnes I. Heine2, Stephanie L. Terzulli1,2, Sacha Gnjatic3, Gerd Ritter3, Achim A. Jungbluth3, James P. Allison1, Lloyd J. Old3 and Jedd D. Wolchok1,2

1Ludwig Center for Cancer Immunotherapy, Immunology Program, Sloan-Kettering Institute, New York, NY 10065, USA

2Melanoma/Sarcoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA

3Ludwig Institute for Cancer Research, New York Branch, New York, NY 10065, USA

Contributed by: LJ Old

Keywords: human, melanoma, ipilimumab, case report, immunogram, immunoediting

Abstract

Melanoma patients treated with anti-CTLA-4 have shown a range of anti-tumor responses. In this report, we describe the response of a single patient to anti-CTLA-4, with individual lesions disappearing, others stabilizing, and others progressing. These responses can be viewed as a clear manifestation of cancer immunoediting and its three phases of elimination, equilibrium and escape, with each tumor in this patient being at a discrete stage in the process. The patient's course and associated immunological monitoring and other laboratory data are presented in an immunogram, a way to visualize temporal associations between the multiple clinical and laboratory parameters.